Effect of the 3q26-coding oncogene SEC62 as a potential prognostic marker in patients with ovarian neoplasia

• DOI: 10.3389/fphys.2022.1054508
• Publication Date: 2023-01-04T09:29:03Z
• Authors: Julia C. Radosa; Mariz Kasoha; Anne-Christine Sc...; Zoltan F. Takacs; Askin Kaya; Marc P. Radosa; Barbara Linxweiler; Maximilian Linxwe...; Rainer M. Bohle; Mathias Wagner; Gudrun Wagenpfeil; Erich-Franz Solom...; Julia S. M. Zimme...
• Keywords: Ovarian tumor; Pathogenesis

With approximately 220,000 newly diagnosed cases per year, ovarian cancer is among the most frequently occurring cancers women and second leading cause of death from gynecological malignancies worldwide. About 70% these are in advanced stages (FIGO IIB-IV), with a 5-year survival rate 20-30%. Due to poor prognosis this disease, research has focused on its pathogenesis identification prognostic factors. One possible approach for biological markers tumor entity-specific genetic "driver mutations". such mutation 3q26 amplification driver SEC62, which been identified as relevant cancer. This study was conducted investigate role SEC62 malignancies. Patients neoplasias (borderline tumors ovary cancer) who were treated between January 2007 April 2019 at Department Gynecology Obstetrics, Saarland University Hospital, included retrospective study. expression tissue samples taken during clinical treatment assessed immunohistochemically, calculation immunoreactivity scores according Remmele Stegner, Pathologe, 1987, 8, 138-140. Correlations TNM stage, histological subtype, entity, oncological outcomes (progression-free overall survival) examined. The sample comprised 167 patients (123 44 borderline ovary) median age 60 (range, 15-87) years. At time diagnosis, 77 (46%) FIGO stage III. All slides showed overexpression cells no other cells. Median 8 2-12) 9 4-12) ovary. well an immunoreactive score (IRS) ≤ improved compared those presenting IRS >9 (p = 0.03). seems be biomarker